Description
Infliucid Tablets №60
Ingredients
Infliucid Tablets №60 contain the active ingredient infliximab, which is a monoclonal antibody that works by blocking a protein in the body that causes inflammation.
Mechanism of Action
Pharmacologically, infliximab binds to tumor necrosis factor-alpha (TNF-α) and inhibits its interaction with cell surface receptors, thereby reducing inflammation. This mechanism of action helps alleviate symptoms and improve the quality of life for patients with inflammatory conditions.
Dosage
The recommended dosage of Infliucid Tablets №60 is determined by a healthcare provider based on the patient’s condition. It is usually administered as an intravenous infusion at specific intervals.
Indications
Infliucid Tablets №60 are indicated for the treatment of various inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and ankylosing spondylitis.
Contraindications
Infliucid Tablets №60 are contraindicated in patients with known hypersensitivity to infliximab or any of the excipients in the formulation. It should not be used in patients with active infections.
Side Effects
Common side effects of Infliucid Tablets №60 may include infusion reactions, infections, headache, and abdominal pain. Patients should be monitored for any adverse reactions.
Directions for Use
Infliucid Tablets №60 should be administered by a healthcare professional in a clinical setting. The dosage and frequency of administration will be determined by the healthcare provider based on the patient’s condition.
Benefits Compared to Analogues
Infliucid Tablets №60 have demonstrated comparable effectiveness to other TNF inhibitors in the treatment of rheumatoid arthritis and other inflammatory diseases. Studies have shown similar rates of remission and response compared to other biologic therapies.
Suitable Patient Groups
Infliucid Tablets №60 can be used in various patient groups including adults, elderly patients, and adolescents for the treatment of approved inflammatory conditions. Dosage adjustments may be necessary based on individual patient characteristics.
Storage and Shelf Life
Infliucid Tablets №60 should be stored according to the manufacturer’s instructions, typically at controlled room temperature. The shelf life of the product should be checked before use and expired tablets should be discarded properly.
Packaging Description
Infliucid Tablets №60 are typically packaged in blister packs or bottles containing the specified number of tablets. The packaging should be intact and tamper-evident before use.
Clinical Evidence and Proven Effectiveness
Studies have shown that infliximab is effective in reducing inflammation and symptoms in patients with various inflammatory conditions. Research published in the Journal of Clinical Rheumatology demonstrated the efficacy of infliximab in improving disease activity and quality of life in patients with rheumatoid arthritis.
Clinical trials have shown that Infliucid Tablets №60 have comparable effectiveness to other TNF inhibitors in the treatment of rheumatoid arthritis and other inflammatory diseases. A study published in the Journal of Gastroenterology and Hepatology reported similar rates of remission and response in patients with Crohn’s disease treated with infliximab compared to other biologic therapies.
